Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Comment by TenFingerson Jul 04, 2018 3:09pm
89 Views
Post# 28268697

RE:RE:RE:RE:RE:RE:RE:Pet lovers. Lib better get off the pot.

RE:RE:RE:RE:RE:RE:RE:Pet lovers. Lib better get off the pot.I'm starting to wonder if we are reading the same thing at all...

Very first paragraph (that you are referring to):

"Vancouver, BC – June 1, 2017Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSEHN3P) (the “Company” or “Liberty Leaf) announced today that it has finalized the statement of work model and design for testing the efficacy of Cannabinoids (CBD) in canine osteoarthritis, which includes hip dysplasia, elbow dysplasia and stifle Degenerative Joint Disease (DJD)."

What is this saying Ovechkin? To me, this is stating, and let me quote: "it [Liberty Leaf] has finalized the statement of work model and design for testing".  This means the study design is FINALIZED. It is ready to go.

In fact, the title of this article is "Liberty Leaf In Collaboration With ESEV R&D Launches Study To Demonstrate the Efficacy of CBD for Pain Management in Canine Osteoarthritis"

Let me highlight some words in this title: "LAUNCHES STUDY". 

Later, in this exact article, and I quote again: "The study will include large mixed-breed dogs, which will receive the drug or placebos in the active phase of study [this to me is the clinical trial!], with the timeline to finish the activity estimated at between six to eight months. The focus will be on treating chronic pain due to hip dysplasia, and/or elbow dysplasia, or stifle DJD due to Canine Cruciate Ligament Disease (CCLD)."

So, to me, whoever wrote this article has not clearly differentiated between the trials and whatever this period of time between June 1 and December 20th was. I read this through as a study with an anticipated duration of time.

I wasn't expecting results at 6-8 months, I was expecting this phase to be completed and results to follow shortly thereafter, and hopefully news of an additional planned spin-off clinical trial.

At any rate, this debate is on interpretation... It is easy to look back and say "oh yeah, this is clearly what they meant". For me, in no place in that article do I see anything about a 6-8 month period BEFORE the 6-8 month period. lol 


Ovechkin wrote: Oh vey read the first paragraph LOL it says outline and design clearly. I’m not sure what else to say other than read. It did not stated results would be in 6-8 months from that release.. it stated the trials took 6-8 months 


<< Previous
Bullboard Posts
Next >>